We are live on ! Find out more
GERM

Amplify Treatments, Testing and Advancements ETF
GERM

Delisted

GERM was delisted on the 5th of September, 2024.

Back to rankings

14 hedge funds and large institutions have $4.93M invested in Amplify Treatments, Testing and Advancements ETF in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less funds holding

Funds holding: 17 → 14 (-3)

21% less capital invested

Capital invested by funds: $6.27M → $4.93M (-$1.34M)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
14
Holders Change
-3
Holders Change %
-17.65%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$227K
2
UBS Group
UBS Group
Switzerland
+$9.53K
3
Morgan Stanley
Morgan Stanley
New York
+$52

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$474K
2
GBWM
Granite Bay Wealth Management
New Hampshire
-$413K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$182K
4
Osaic Holdings
Osaic Holdings
Arizona
-$59.9K
5
Citadel Advisors
Citadel Advisors
Florida
-$35.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
GBWM
1
Granite Bay Wealth Management
New Hampshire
$3.63M -$413K -23,675 -10%
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$668K +$227K +12,994 +61%
Citadel Advisors
3
Citadel Advisors
Florida
$321K -$35.3K -2,026 -11%
Goldman Sachs
4
Goldman Sachs
New York
$203K -$474K -27,168 -72%
HI
5
Harbour Investments
Wisconsin
$34.2K – – –
FDCDDQ
6
Federation des caisses Desjardins du Quebec
Quebec, Canada
$29.2K – – –
UBS Group
7
UBS Group
Switzerland
$10.7K +$9.53K +546 New
CHC
8
City Holding Co
West Virginia
$7.82K – – –
Osaic Holdings
9
Osaic Holdings
Arizona
$7.69K -$59.9K -3,433 -90%
Bank of Montreal
10
Bank of Montreal
Ontario, Canada
$5.99K – – –
TAM
11
Tucker Asset Management
Colorado
$4.52K – – –
IA
12
IFP Advisors
Florida
$3.91K – – –
SPIA
13
Steward Partners Investment Advisory
New York
$3.13K – – –
Morgan Stanley
14
Morgan Stanley
New York
$88 +$52 +3 +300%
Commonwealth Equity Services
15
Commonwealth Equity Services
Massachusetts
– -$182K -10,180 Closed
BAM
16
Byrne Asset Management
New Jersey
– -$6K -350 Closed
LF
17
Lee Financial
Texas
– -$2.04K -114 Closed
BHWM
18
Beaird Harris Wealth Management
Texas
– -$839 -47 Closed

GERM Hedge Fund Activity: Q4 2023 in Review

14 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q4 2023, worth a combined $4.93M — down 21% from $6.27M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of GERM and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Susquehanna International Group, adding an estimated $227K. The largest seller was Goldman Sachs, cutting an estimated $474K.

  • 14 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q4 2023, down from 17 in Q3 2023.
  • Funds reported $4.93M of Amplify Treatments, Testing and Advancements ETF stock for Q4 2023, down 21% quarter-over-quarter.
  • 1 fund opened new Amplify Treatments, Testing and Advancements ETF positions in Q4 2023 and 4 closed out, a net change of -3 holders.
  • The largest Amplify Treatments, Testing and Advancements ETF buyer in Q4 2023 was Susquehanna International Group, an estimated $227K added.
  • The largest Amplify Treatments, Testing and Advancements ETF seller in Q4 2023 was Goldman Sachs, an estimated $474K sold.

Based on aggregated 13F filings for Q4 2023.